Outlook Therapeutics Inc (NASDAQ: OTLK)’s stock price has soared by 2.79 in relation to previous closing price of 1.79. Nevertheless, the company has seen a loss of -1.60% in its stock price over the last five trading days. globenewswire.com reported 2025-06-10 that ISELIN, N.J., June 10, 2025 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the Scottish Medicines Consortium (SMC) acceptance of LYTENAVA™ (bevacizumab gamma) for use within NHS Scotland for the treatment of wet age-related macular degeneration (wet AMD). LYTENAVA™ (bevacizumab gamma) is the first and only licensed ophthalmic formulation of bevacizumab for use in treating wet AMD in adults in the United Kingdom (UK) and has an initial 10 years of market exclusivity from the date of initial marketing authorization from the Medicines and Healthcare products Regulatory Agency.
Is It Worth Investing in Outlook Therapeutics Inc (NASDAQ: OTLK) Right Now?
Moreover, the 36-month beta value for OTLK is 0.30. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for OTLK is 21.22M and currently, short sellers hold a 15.17% of that float. On June 13, 2025, OTLK’s average trading volume was 537.20K shares.
OTLK’s Market Performance
The stock of Outlook Therapeutics Inc (OTLK) has seen a -1.60% decrease in the past week, with a -9.36% drop in the past month, and a 24.32% gain in the past quarter. The volatility ratio for the week is 2.79%, and the volatility levels for the past 30 days are at 3.66% for OTLK. The simple moving average for the last 20 days is 4.25% for OTLK’s stock, with a simple moving average of -40.12% for the last 200 days.
Analysts’ Opinion of OTLK
BTIG Research, on the other hand, stated in their research note that they expect to see OTLK reach a price target of $50. The rating they have provided for OTLK stocks is “Buy” according to the report published on March 27th, 2024.
Chardan Capital Markets gave a rating of “Buy” to OTLK, setting the target price at $3 in the report published on February 15th of the previous year.
OTLK Trading at 16.85% from the 50-Day Moving Average
After a stumble in the market that brought OTLK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.11% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OTLK starting from KENYON LAWRENCE A, who purchase 5,000 shares at the price of $5.69 back on Sep 26 ’24. After this action, KENYON LAWRENCE A now owns 5,946 shares of Outlook Therapeutics Inc, valued at $28,446 using the latest closing price.
Stock Fundamentals for OTLK
The total capital return value is set at 2.16.
Based on Outlook Therapeutics Inc (OTLK), the company’s capital structure generated -0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -100.78. The debt to equity ratio resting at -0.01. The interest coverage ratio of the stock is -669.74.
Currently, EBITDA for the company is -71.59 million with net debt to EBITDA at 0.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.72.
Conclusion
To wrap up, the performance of Outlook Therapeutics Inc (OTLK) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
